Drug Trial News

RSS

Children with neuroblastomas may benefit from new drug cocktail

Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumor drugs as well as chemotherapy, a new trial has found.

9 Jan 2024

Breakthrough drug halts lung cancer and brain metastases

D'Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small cell lung cancer (NSCLC).

5 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits

Researchers identified 5-hydroxytryptamine 2A (5-HT2A) receptor (5-HT2AR) signaling pathways associated with psychedelic potential.

19 Dec 2023

Psilocybin may benefit individuals with cancer and major depression

Results from a phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe, may benefit individuals with cancer and major depression.

18 Dec 2023

Experimental drug paired with a standard-care medication offers hope for kidney disease patients

In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria -; albumin in urine, a sign of kidney damage -; for 50% of participants.

15 Dec 2023

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Researchers find powerful combo weapon against aggressive lymphoma

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

12 Dec 2023

Study highlights the necessity to refine the design of randomized cancer drugs trials in China

More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine by Professor Xiaodong Guan of Peking University, China, and colleagues.

12 Dec 2023

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.

From SolasCure 12 Dec 2023

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year.

11 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Personalized treatment for leukemia results in longer life and fewer side effects

Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found.

11 Dec 2023

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Previous
1
...
9
10
11
12
13
14
15
...
1143
Next

Drug Trial News

Children with neuroblastomas may benefit from new drug cocktail

Breakthrough drug halts lung cancer and brain metastases

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits

Psilocybin may benefit individuals with cancer and major depression

Experimental drug paired with a standard-care medication offers hope for kidney disease patients

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Researchers find powerful combo weapon against aggressive lymphoma

Study highlights the necessity to refine the design of randomized cancer drugs trials in China

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

New combination treatment offers hope for older patients with mantle cell lymphoma

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

Personalized treatment for leukemia results in longer life and fewer side effects

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News